DCI Advisors Ltd
(the "Company" or "DCI")
Delay in Publication of Annual Results and Temporary Suspension
1 November 2024
The Board of the Company provides a further update with respect to its audited annual results for the year end 31 December 2023 ("Annual Results") and its temporary suspension from trading on AIM.
Delay in Publication of Annual Results
DCI's auditor is KPMG Cyprus in cooperation with KPMG Greece and KPMG Croatia who audit the assets in those respective countries.
On the 18th June, the Company informed shareholders that the audit was expected to take until at least 9 August 2024, which was the best indication of timing the Board had received at the time.
A further update was issued on 16 September 2004 advising that the Audited Annual Results would be published during October 2024.
As at today's date, the Audit has not been completed. KPMG continue to work on this and the Company now believes that the audited Annual Results together with the interim results for the 6 months to 30 June 2024 should be published during December.
Further updates will be made when available.
Temporary Suspension
As announced on 18 June 2024, DCI's ordinary shares of €0.01 each ("Ordinary Shares") were suspended on 1 July 2024 after the Company was unable to publish its audited annual results.
DCI's Ordinary Shares remain suspended for the time being, and the suspension will be lifted after the audited Annual and Interim Results are published.
Further announcements will be made as required.
Enquiries
| DCI Advisors Ltd Nicolai Huls / Nick Paris, Managing Directors | +44 (0) 7738 470550 |
| Cavendish Capital Markets (Nominated Adviser & Broker) James King / Jonny Franklin-Adams / Edward Whiley / (Corporate Finance) Pauline Tribe (Sales) |
+44 (0) 20 7220 0500 |
| FIM Capital Limited (Administrator) Lesley Lennon (Corporate Governance) |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
